Telix to acquire RLS Radiopharmacies for $250m.

Telix, a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals and associated medical devices, agreed to acquire RLS Radiopharmacies, a radiopharmacy network, for $250m. "Our vision is to build a radiometal production and distribution network fit for the future. By combining the ARTMS platform and the RLS network, we can scale up the production of key isotopes and build a stable and consistent supply of PET and SPECT diagnostic tracers, along with therapeutic radiopharmaceuticals across the U.S. for the benefit of Telix, our partners and the patients we serve," Christian Behrenbruch, Telix Managing Director and Group CEO.